Nutrition & DietPress Release

Vitamin B12 corrects growth defects in worms modeling a rare splicing disorder

In C. elegans carrying a Verheij syndrome-linked splicing mutation, B12 restored metabolism and growth. Human blood samples show similar changes; no patient trial yet.

Wednesday, November 18, 2026 0 views
Published in ScienceDaily Nutrition
Article visualization: Vitamin B12 corrects growth defects in worms modeling a rare splicing disorder

Summary

Researchers at the Max Planck Institute for Biology of Ageing found that vitamin B12 largely reversed growth and developmental defects in C. elegans roundworms carrying a mutation in an RNA splicing gene linked to Verheij syndrome, a rare human disorder with short stature and developmental delay. The mutation disrupted metabolic pathways that depend on B12, and added B12 restored those pathways to normal. The team also analyzed public human cell datasets and blood samples from Verheij patients, and found similar metabolic changes. This is a worm model plus a human biomarker-level observation. Whether B12 supplementation improves symptoms in people has not been tested, so it is not a treatment recommendation. The work links RNA splicing to vitamin-dependent metabolism, a connection relevant to growth and aging biology.

Detailed Summary

Why it matters: RNA splicing, the editing of messenger RNA before protein production, is a core cellular process that is known to become dysregulated with age. Mutations in splicing genes cause developmental disorders such as Verheij syndrome, which involves growth impairment, short stature and developmental delay. Few treatments exist, so a mechanism pointing to a cheap, well-known nutrient is notable.

Main findings: The work began as a search for new lifespan-influencing genes in C. elegans. Worms with a mutation in a splicing gene that is also linked to Verheij syndrome grew slowly and stayed small, resembling features of the human disorder. Genetic screens and metabolic analysis showed that the mutation disrupted specific vitamin B12-dependent metabolic pathways. Supplementing B12 restored those pathways to normal and largely corrected the developmental abnormalities.

Key insights: The mechanism is the surprising part. A change in a fundamental RNA-processing step had a targeted effect on B12-dependent metabolism, which suggests a bridge between splicing and nutrient metabolism. The researchers then examined public human cell datasets and collected blood samples from patients with Verheij syndrome, with a neuropediatrician at University Hospital Cologne. They found similar metabolic changes, suggesting the same B12-related pathways may be involved in people. The article does not report lifespan results from the worm model, so the evidence covers mechanism and developmental function, not longevity.

Practical implications: There is no basis yet for patients or healthy people to use B12 for this purpose. The finding is a hypothesis for clinical investigation, and may inspire metabolic approaches to other splicing-related disorders.

Caveats: The rescue was shown only in worms. The human data are metabolic observations, not evidence of symptom improvement, and the article states that benefit from B12 supplementation in patients has not been established. Patient sample size is not given in the excerpt, and the text was cut off.

Key Findings

  • In C. elegans with a Verheij syndrome-linked splicing gene mutation, growth was slowed and body size reduced.
  • The mutation disrupted B12-dependent metabolic pathways; added vitamin B12 restored them to normal in worms.
  • B12 largely corrected the worms' developmental abnormalities, a mechanism and function result, not a lifespan result.
  • Public human cell data and patient blood samples showed similar metabolic changes, but this is not evidence of clinical benefit.
  • Whether B12 supplementation improves symptoms in Verheij patients has not been established.

Methodology

This is a university press-release news report on a preclinical study in C. elegans, supplemented by analysis of public human cell datasets and patient blood samples. The source is a reputable aging-research institute, but the excerpt gives no patient numbers, effect sizes or journal details. Evidence covers mechanism and developmental function in worms; no lifespan outcome or patient treatment data are reported.

Study Limitations

Rescue was shown only in a worm model, and the human data are metabolic observations from an unspecified number of patients. The excerpt is truncated and gives no dose, journal or statistics, so check the primary paper. Relevance to normal aging is indirect.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: